Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback